- Author: Robert H Graham, MD; Chief Editor: Hampton Roy, Sr, MD more...
Bacterial endophthalmitis (see the image below) is an inflammatory reaction of the intraocular fluids or tissues caused by microbial organisms. Bacteria may gain entry into the eye via corneal or scleral trauma (surgical or accidental) or hematogenously. If not properly treated, bacterial endophthalmitis can result in complete vision loss and persistent ocular pain.
Signs and symptoms
The clinical presentation depends on the route of entry, the infecting organism, and the duration of the disease. In general, patients complain of the following:
A red eye
Deep ocular pain
Bacterial endophthalmitis is classified on the basis of routes of entry (ie, exogenous or endogenous). Disease from exogenous sources includes the following:
Acute postoperative (< 6 wk postoperative) [2, 3] ; usually occurs 2-10 days after surgery
Delayed onset or chronic pseudophakic postoperative (>6 wk postoperative) 
Filtering bleb associated
Posttraumatic– History of trauma is present, and infection usually progresses rapidly 
On physical examination, general findings in bacteria endophthalmitis are as follows:
Visual acuity decreased below the level expected
Anterior chamber cells and flare
Fibrin membrane formation
Loss of red reflex
Retinal periphlebitis if view of fundus possible 
Specific physical examination findings are as follows:
Delayed onset or chronic cases– Occasionally, a white plaque within the equator of the remaining lens capsule
Filtering bleb associated– A purulent bleb is seen occasionally with areas of necrosis in the sclera from the use of antimetabolites
Posttraumatic– Evidence of penetrating trauma is seen with the possibility of an intraocular foreign body [7, 8]
Endogenous– Patients may appear systemically ill
See Clinical Presentation for more detail.
Perform culture and sensitivity studies on aqueous and vitreous samples to determine the type of organism and antibiotic sensitivity.[9, 10] If endogenous bacterial endophthalmitis is suspected, a systemic workup for the source is required, with cultures of blood, sputum, and urine.
Anterior chamber tap
Vitreous biopsy: A 23-gauge vitrectomy cutter may be used if available
For anterior chamber taps, a 30-gauge needle on a tuberculin syringe is used to obtain a 0.1-mL sample under topical anesthesia through the limbus. For vitreous taps, a sub-Tenon or retrobulbar block with lidocaine with epinephrine is given, and a 21-gauge needle on a tuberculin syringe is used to obtain an adequate vitreous sample of 0.1-0.2 mL.
Perform B-scan ultrasound of the posterior pole if view of fundus is poor
Typically, choroidal thickening and ultrasound echoes in the anterior and posterior vitreous support the diagnosis
Occasionally, another source of inflammation other than or in addition to bacteria, such as retained lens material, may be seen
The ultrasound also provides a baseline prior to intraocular intervention and allows assessment of the posterior vitreous face and areas of possible traction 
Rarely, a retinal detachment is seen concurrently with endophthalmitis
Other imaging studies
In traumatic cases, a CT scan may show thickening of the sclera and uveal tissues associated with various degree of increased density in the vitreous and periocular soft tissue structures. For possible endogenous cases, imaging modalities to rule out potential sources of infection include 2-dimensional echocardiography and chest x-ray.
See Workup for more detail.
Bacterial endophthalmitis is an ocular emergency, and urgent treatment is required to reduce the potential of significant visual loss.[13, 14] All patients should have therapy consisting of the following[15, 16, 17, 18] :
Intravitreal and topical antibiotics
Topical steroids (eg, ophthalmic prednisolone, dexamethasone, triamcinolone)
Cycloplegics (eg, atropine ophthalmic)
When the inflammation is severe, systemic and periocular therapy may be used in non–cataract-induced, delayed onset, filtering bleb–associated, and posttraumatic endophthalmitis. In endogenous endophthalmitis, systemic, topical, and possibly periocular therapy is usually required.
Vancomycin - For patients who cannot receive or have failed to respond to penicillins and cephalosporins or have infections with resistant staphylococci; Assaad et al showed that vancomycin was effective against 99.6% of gram-positive bacterial endophthalmitis isolates tested  ; Ahmed et reported that intravitreal, rather than intravenous, vancomycin is necessary for the treatment of bacterial endophthalmitis.  It is not necessary to monitor vancomycin levels when administered via intravitreal injection.
Ceftazidime - First-line choice for intravitreal gram-negative coverage; ceftazidime was effective against 100% of gram-negative bacterial endophthalmitis isolates in a study by Assaad et al 
Amikacin - Second-line choice for intravitreal injection for gram-negative coverage
Ciprofloxacin/ofloxacin/levofloxacin/moxifloxacin/gatifloxacin ophthalmic - Fluoroquinolones with activity against Pseudomonas, streptococci, MRSA, S epidermidis, and most gram-negative organisms; may have limited activity against anaerobes
Surgical intervention is usually performed urgently; however, elective surgery may suffice in delayed-onset cases. Indications for surgical therapy include the following:
Acute pseudophakic postoperative– When the presenting vision is light perception or worse 
Delayed onset or chronic postoperative– If marked inflammation or a subcapsular plaque is identified, surgical removal is required
Filtering bleb–associated– If marked inflammation is present
Posttraumatic– If marked inflammation or rapid onset occurs
Bacterial endophthalmitis is an inflammatory reaction of the intraocular fluids or tissues caused by microbial organisms. See the images below.
The entry of bacteria into the eye occurs from a breakdown of the ocular barriers. Penetration through the cornea or sclera results in an exogenous insult to the eye. If the entry is through the vascular system, then an endogenous route occurs. After the bacteria gain entry into the eye, rapid proliferation occurs.
The vitreous acts as a superb medium for bacteria growth, and, in the past, animal vitreous was used as a culture medium. Bacteria, as foreign objects, incite an inflammatory response. The cascade of inflammatory products occurs resulting in an increase in the blood-ocular barrier breakdown and an increase in inflammatory cell recruitment. The damage to the eye occurs from the breakdown of the inflammatory cells releasing the digestive enzymes as well as the possible toxins produced by the bacteria. Destruction occurs at all tissue levels that are in contact with the inflammatory cells and toxins.
Incidence after intraocular surgery is less than 0.1%. Incidence of culture-proven endophthalmitis is similar to that of extracapsular cataract extraction and phacoemulsification.
If not properly treated, a risk of complete vision loss and the possibility of persistent ocular pain exist. Infection very rarely spreads beyond the confines of the sclera and tracks into surrounding tissue structures.
Forster RK. Etiology and diagnosis of bacterial postoperative endophthalmitis. Ophthalmology. 1978 Apr. 85(4):320-6. [Medline].
Arshinoff SA, Bastianelli PA. Incidence of postoperative endophthalmitis after immediate sequential bilateral cataract surgery. J Cataract Refract Surg. 2011 Dec. 37(12):2105-14. [Medline].
Thompson JT, Parver LM, Enger CL, Mieler WF, Liggett PE. Infectious endophthalmitis after penetrating injuries with retained intraocular foreign bodies. National Eye Trauma System. Ophthalmology. 1993 Oct. 100(10):1468-74. [Medline].
Irvine WD, Flynn HW Jr, Murray TG, Rubsamen PE. Retained lens fragments after phacoemulsification manifesting as marked intraocular inflammation with hypopyon. Am J Ophthalmol. 1992 Nov 15. 114(5):610-4. [Medline].
Packer AJ, Weingeist TA, Abrams GW. Retinal periphlebitis as an early sign of bacterial endophthalmitis. Am J Ophthalmol. 1983 Jul. 96(1):66-71. [Medline].
Mieler WF, Ellis MK, Williams DF, Han DP. Retained intraocular foreign bodies and endophthalmitis. Ophthalmology. 1990 Nov. 97(11):1532-8. [Medline].
Okada AA, Johnson RP, Liles WC, D'Amico DJ, Baker AS. Endogenous bacterial endophthalmitis. Report of a ten-year retrospective study. Ophthalmology. 1994 May. 101(5):832-8. [Medline].
Donahue SP, Kowalski RP, Jewart BH, Friberg TR. Vitreous cultures in suspected endophthalmitis. Biopsy or vitrectomy?. Ophthalmology. 1993 Apr. 100(4):452-5. [Medline].
Hariprasad SM, Shah GK, Chi J, Prince RA. Determination of aqueous and vitreous concentration of moxifloxacin 0.5% after delivery via a dissolvable corneal collagen shield device. J Cataract Refract Surg. 2005 Nov. 31(11):2142-6. [Medline].
Chiquet C, Cornut PL, Benito Y, et al. Eubacterial PCR for bacterial detection and identification in 100 acute postcataract surgery endophthalmitis. Invest Ophthalmol Vis Sci. 2008 May. 49(5):1971-8. [Medline].
Chan IM, Jalkh AE, Trempe CL, Tolentino FI. Ultrasonographic findings in endophthalmitis. Ann Ophthalmol. 1984 Aug. 16(8):778-84. [Medline].
Callegan MC, Gilmore MS, Gregory M, et al. Bacterial endophthalmitis: therapeutic challenges and host-pathogen interactions. Prog Retin Eye Res. 2007 Mar. 26(2):189-203. [Medline].
Garat M, Moser CL, Alonso-Tarres C, Martin-Baranera M, Alberdi A. Intracameral cefazolin to prevent endophthalmitis in cataract surgery: 3-year retrospective study. J Cataract Refract Surg. 2005 Nov. 31(11):2230-4. [Medline].
Flynn HW Jr, Pulido JS, Pflugfelder SC, et al. Endophthalmitis therapy: changing antibiotic sensitivity patterns and current therapeutic recommendations. Arch Ophthalmol. 1991 Feb. 109(2):175-6. [Medline].
Costello P, Bakri SJ, Beer PM, et al. Vitreous penetration of topical moxifloxacin and gatifloxacin in humans. Retina. 2006 Feb. 26(2):191-5. [Medline].
Gan IM, Ugahary LC, van Dissel JT, et al. Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial. Graefes Arch Clin Exp Ophthalmol. 2005 Dec. 243(12):1200-5. [Medline].
Smiddy WE, Smiddy RJ, Ba'Arath B, et al. Subconjunctival antibiotics in the treatment of endophthalmitis managed without vitrectomy. Retina. 2005 Sep. 25(6):751-8. [Medline].
Assaad D, Wong D, Mikhail M, Tawfik S, Altomare F, Berger A, et al. Bacterial endophthalmitis: 10-year review of the culture and sensitivity patterns of bacterial isolates. Can J Ophthalmol. 2015 Dec. 50 (6):433-7. [Medline].
Ahmed S, Kuruvilla O, Yee DC, Aggarwal H, Li Y, Edwards P, et al. Intraocular penetration of systemic antibiotics in eyes with penetrating ocular injury. J Ocul Pharmacol Ther. 2014 Dec. 30 (10):823-30. [Medline].
Miller JJ, Scott IU, Flynn HW Jr, Smiddy WE, Newton J, Miller D. Acute-onset endophthalmitis after cataract surgery (2000-2004): incidence, clinical settings, and visual acuity outcomes after treatment. Am J Ophthalmol. 2005 Jun. 139(6):983-7. [Medline].
Mandelbaum S, Forster RK, Gelender H, Culbertson W. Late onset endophthalmitis associated with filtering blebs. Ophthalmology. 1985 Jul. 92(7):964-72. [Medline].
Hariprasad SM, Shah GK, Mieler WF, et al. Vitreous and aqueous penetration of orally administered moxifloxacin in humans. Arch Ophthalmol. 2006 Feb. 124(2):178-82. [Medline].
Gregory M, Callegan MC, Gilmore MS. Role of bacterial and host factors in infectious endophthalmitis. Chem Immunol Allergy. 2007. 92:266-75. [Medline].
Kunimoto DY, Das T, Sharma S, et al. Microbiologic spectrum and susceptibility of isolates: part I. Postoperative endophthalmitis. Endophthalmitis Research Group. Am J Ophthalmol. 1999 Aug. 128(2):240-2. [Medline].
Rathinam SR, Rao NA. Sympathetic ophthalmia following postoperative bacterial endophthalmitis: a clinicopathologic study. Am J Ophthalmol. 2006 Mar. 141(3):498-507. [Medline].
Somani S, Grinbaum A, Slomovic AR. Postoperative endophthalmitis: incidence, predisposing surgery, clinical course and outcome. Can J Ophthalmol. 1997 Aug. 32(5):303-10. [Medline].
Winward KE, Pflugfelder SC, Flynn HW Jr, Roussel TJ, Davis JL. Postoperative Propionibacterium endophthalmitis. Treatment strategies and long-term results. Ophthalmology. 1993 Apr. 100(4):447-51. [Medline].
Greenfield DS, Suner IJ, Miller MP, Kangas TA, Palmberg PF, Flynn HW Jr. Endophthalmitis after filtering surgery with mitomycin. Arch Ophthalmol. 1996 Aug. 114(8):943-9. [Medline].
Bouza E, Grant S, Jordan C, Yook RH, Sulit HL. Bacillus cereus endogenous panophthalmitis. Arch Ophthalmol. 1979 Mar. 97(3):498-9. [Medline].
Soheilian M, Rafati N, Mohebbi MR, et al. Prophylaxis of acute posttraumatic bacterial endophthalmitis: a multicenter, randomized clinical trial of intraocular antibiotic injection, report 2. Arch Ophthalmol. 2007 Apr. 125(4):460-5. [Medline].
Abrishami M, Hashemi B, Abrishami M, Abnous K, Razavi-Azarkhiavi K, Behravan J. PCR detection and identification of bacterial contaminants in ocular samples from post-operative endophthalmitis. J Clin Diagn Res. 2015 Apr. 9 (4):NC01-3. [Medline].
Aaberg TM Jr, Flynn HW Jr, Schiffman J, Newton J. Nosocomial acute-onset postoperative endophthalmitis survey. A 10-year review of incidence and outcomes. Ophthalmology. 1998 Jun. 105(6):1004-10. [Medline].
Barza M, Pavan PR, Doft BH, et al. Evaluation of microbiological diagnostic techniques in postoperative endophthalmitis in the Endophthalmitis Vitrectomy Study. Arch Ophthalmol. 1997 Sep. 115(9):1142-50. [Medline].
Cohen SM, Flynn HW Jr, Murray TG, Smiddy WE. Endophthalmitis after pars plana vitrectomy. The Postvitrectomy Endophthalmitis Study Group. Ophthalmology. 1995 May. 102(5):705-12. [Medline].
Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol. 1995 Dec. 113(12):1479-96. [Medline].
Han DP, Wisniewski SR, Wilson LA, et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol. 1996 Jul. 122(1):1-17. [Medline].
Ng JQ, Morlet N, Pearman JW, et al. Management and outcomes of postoperative endophthalmitis since the endophthalmitis vitrectomy study: the Endophthalmitis Population Study of Western Australia (EPSWA)'s fifth report. Ophthalmology. 2005 Jul. 112(7):1199-206. [Medline].
Storey P, Dollin M, Rayess N, Pitcher J, Reddy S, Vander J, et al. The effect of prophylactic topical antibiotics on bacterial resistance patterns in endophthalmitis following intravitreal injection. Graefes Arch Clin Exp Ophthalmol. 2016 Feb. 254 (2):235-42. [Medline].
Gupta A, Orlans HO, Hornby SJ, Bowler IC. Microbiology and visual outcomes of culture-positive bacterial endophthalmitis in Oxford, UK. Graefes Arch Clin Exp Ophthalmol. 2014 Nov. 252 (11):1825-30. [Medline].
Zhang YQ, Wang WJ. Treatment outcomes after pars plana vitrectomy for endogenous endophthalmitis. Retina. 2005 Sep. 25(6):746-50. [Medline].
van Kooij B, Rothova A, de Vries P. The pros and cons of intravitreal triamcinolone injections for uveitis and inflammatory cystoid macular edema. Ocul Immunol Inflamm. 2006 Apr. 14(2):73-85. [Medline].
Kowalski RP, Romanowski EG, Mah FS, Yates KA, Gordon YJ. Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model. Am J Ophthalmol. 2005 Sep. 140(3):497-504. [Medline].
Deramo VA, Lai JC, Winokur J, Luchs J, Udell IJ. Visual outcome and bacterial sensitivity after methicillin-resistant Staphylococcus aureus-associated acute endophthalmitis. Am J Ophthalmol. 2008 Mar. 145(3):413-417. [Medline].
Alfonso E, Crider J. Ophthalmic infections and their anti-infective challenges. Surv Ophthalmol. 2005 Nov. 50 Suppl 1:S1-6. [Medline].
Ayata A, Uzun G, Unal M, Yildiz S, Bilge AH. Does hyperbaric oxygen therapy improve outcome in bacterial endophthalmitis?. Med Hypotheses. 2008 Sep. 71(3):470-1. [Medline].
Boggs W. Bacterial Virulence Predicts Visual Prognosis in Post-Op Bacterial Endophthalmitis. Available at http://www.medscape.com/viewarticle/808786. Accessed: August 15, 2013.
Combey de Lambert A, Campolmi N, Cornut PL, Aptel F, Creuzot-Garcher C, Chiquet C. Baseline Factors Predictive of Visual Prognosis in Acute Postoperative Bacterial Endophthalmitis in Patients Undergoing Cataract Surgery. JAMA Ophthalmol. 2013 Jul 25. [Medline].
Iyer MN, He F, Wensel TG, Mieler WF, Benz MS, Holz ER. Clearance of intravitreal moxifloxacin. Invest Ophthalmol Vis Sci. 2006 Jan. 47(1):317-9. [Medline].
Katz HR, Masket S, Lane SS, et al. Absorption of topical moxifloxacin ophthalmic solution into human aqueous humor. Cornea. 2005 Nov. 24(8):955-8. [Medline].
Mamalis N, Edelhauser HF, Dawson DG, Chew J, LeBoyer RM, Werner L. Toxic anterior segment syndrome. J Cataract Refract Surg. 2006 Feb. 32(2):324-33. [Medline].
Prydal JI, Jenkins DR, Lovering A, Watts A. The pharmacokinetics of linezolid in the non-inflamed human eye. Br J Ophthalmol. 2005 Nov. 89(11):1418-9. [Medline].
Suzuki T, Uno T, Kawamura Y, Joko T, Ohashi Y. Postoperative low-grade endophthalmitis caused by biofilm-producing coccus bacteria attached to posterior surface of intraocular lens. J Cataract Refract Surg. 2005 Oct. 31(10):2019-20. [Medline].
Wolner B, Liebmann JM, Sassani JW, Ritch R, Speaker M, Marmor M. Late bleb-related endophthalmitis after trabeculectomy with adjunctive 5-fluorouracil. Ophthalmology. 1991 Jul. 98(7):1053-60. [Medline].